日本版NIH及其制药企业,政策制定·战略规划需要佐证。本研究尝试基于新的指标体系进行制药产业的现状俯瞰与预测未来。连载第三篇着眼于持有在研药物(pipeline)主体的规模及其种类,分析了掌控医药品开发的关键主体。其结果表明美国的强项在于中小企业与创业企业。另一方面,日本中小企业与创业企业没有承担像美国那样的角色。 Japanese version of NIH and its pharmaceutical companies, policy formulation and strategic planning needs evidence. This study attempts to review and predict the future of the pharmaceutical industry based on the new index system. The third installment focuses on the size and type of subjects holding the pipeline and analyzes the key actors that govern the development of pharmaceuticals. The results show that the strength of the United States lies with SMEs and start-ups. On the other hand, Japanese SMEs and start-ups have not assumed the role of the United States.